Caxton Associates LP Makes New $492,000 Investment in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Caxton Associates LP bought a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 25,095 shares of the company’s stock, valued at approximately $492,000.

Other large investors also recently made changes to their positions in the company. Magnetar Financial LLC bought a new stake in Fulgent Genetics during the second quarter worth $257,000. Public Sector Pension Investment Board raised its stake in shares of Fulgent Genetics by 7.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 44,772 shares of the company’s stock worth $878,000 after purchasing an additional 2,956 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Fulgent Genetics in the 2nd quarter worth about $63,000. Divisadero Street Capital Management LP grew its position in Fulgent Genetics by 46.4% during the second quarter. Divisadero Street Capital Management LP now owns 505,212 shares of the company’s stock valued at $9,912,000 after buying an additional 160,212 shares during the period. Finally, Federated Hermes Inc. increased its holdings in Fulgent Genetics by 9.0% during the second quarter. Federated Hermes Inc. now owns 40,981 shares of the company’s stock worth $804,000 after buying an additional 3,374 shares during the last quarter. 48.06% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Fulgent Genetics news, CEO Ming Hsieh sold 2,313 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $22.83, for a total transaction of $52,805.79. Following the sale, the chief executive officer now directly owns 707,275 shares of the company’s stock, valued at $16,147,088.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 4,324 shares of company stock valued at $98,717. 31.76% of the stock is owned by insiders.

Fulgent Genetics Stock Up 1.2 %

Fulgent Genetics stock opened at $21.16 on Friday. The firm has a 50 day moving average price of $22.82 and a 200-day moving average price of $21.65. Fulgent Genetics, Inc. has a twelve month low of $18.91 and a twelve month high of $30.68. The company has a market capitalization of $633.19 million, a P/E ratio of -3.80 and a beta of 1.50.

Fulgent Genetics (NASDAQ:FLGT) last announced its quarterly earnings data on Friday, August 2nd. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.45. The business had revenue of $71.03 million during the quarter, compared to analyst estimates of $69.07 million. Fulgent Genetics had a negative return on equity of 2.75% and a negative net margin of 56.22%. Fulgent Genetics’s revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.33) earnings per share. Equities analysts expect that Fulgent Genetics, Inc. will post -1.46 EPS for the current fiscal year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.